Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Completes Acquisition Of Ilex, Awaits Clolar Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme closes $1 bil. deal the day after receiving Federal Trade Commission approval. Clolar could be Genzyme's first direct presence in oncology therapeutic market; FDA's user fee deadline is Dec. 30.

You may also be interested in...



Campath Antitrust Order Focuses On Off-Label Use In Organ Transplant Market

Schering AG will take over sole rights for development and marketing of Campath as acute therapy for solid organ transplant rejection as a result of the Genzyme/Ilex merger

Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML

Committee concludes that unconfirmed response can be considered useful for evaluating the drug’s effectiveness. FDA’s Pazdur voices concern to committee that Ilex may not have shown “due diligence” in initiating confirmatory trials.

Genzyme Eyeing Fourth Quarter Close For Ilex Merger

Genzyme expects its proposed merger with Ilex to close in the fourth quarter, Genzyme CEO Henri Termeer said

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel